Current diabetes therapies with orally active agents fall into five major classes, which are i) biguanide (metformin) that activates AMP-activated protein kinase (AMPK) [3-6]; ii) sulfonylurea as an insulin secretogue [7-9]; iii) peroxisome proliferator activated receptor (PPAR) γ-subtype activators [10-12]; iv) α-glucosidase inhibitors [13,14]; v) dipeptidyl peptidase IV (DP-4) inhibitors [15-18]. Here, INS is linked to diabetes mellitus.